#Single Nucleotide Polymorphism (SNP) Genotyping Market

[soumyafwr]

https://carbonfacesocial.org/blogs/80773/Single-Nucleotide-Polymorphism-SNP-Genotyping-Market-Size-Analysis-and-Forecast

Single Nucleotide Polymorphism (SNP) Genotyping Market Size, Analysis and Forecast 2031

[niranjan20]

Single Nucleotide Polymorphism (SNP) Genotyping Market" that assess industry size, share & forecast 2026.

[adityarana1687-blog]

Genotyping Market To Surge Beyond $46.5 Billion By 2030

The global genotyping market size is expected to reach USD 46.5 billion by 2030, expanding at a CAGR of 15.6%, according to a new report by Grand View Research Inc. Factors such as the rising prevalence of genetic diseases, rising awareness and research for personalized medicine, and increasing R&D funding for genomics research is expected to contribute to this growth.

Governments in multiple countries are taking various initiatives to provide support and funding to research organizations for personalized medicine, and genotyping research is anticipated to drive the market. For instance, in August 2019, NIH funded USD 4.6 million initial grants to Color, a health technology company, for precision medicine initiatives and development. Similarly, in 2018, the Government of Australia launched the Australian Genomics Health Futures Mission initiative. The government will provide USD 500 million over a period of 10 years for this mission, and the funding will be sourced from Medical Research Future Fund to improve the testing and diagnosis of genetic diseases and for the development of personalized medicine.

An increase in the prevalence of diseases such as cancer, Alzheimer’s disease, and Parkinson’s disease is another factor that is anticipated to drive demand for genotyping-based diagnostic testing. For instance, Roche has products such as Cobas HCV GT products for cervical cancer diagnosis. Additionally, 23&Me provides genetic testing for medical conditions, such as Parkinson's disease and Alzheimer’s disease.

Failed clinical trials cost companies millions of dollars and therefore companies group patients according to their genotypes. Single Nucleotide Polymorphisms (SNP) based genotyping is increasingly being used in pharmacogenomics to study the effect of genetic variations on the difference in response to therapeutics. Genotyping-based treatment administration also helps in overall cost savings.

The COVID-19 pandemic increased the demand for genotyping-based research activities for the development of COVID diagnostics, vaccines, and therapeutics. Many companies, including Qiagen and Thermo Fisher Scientific, have now launched COVID-19 genotyping kits as a result of the growing demand.

Key players leverage strategic partnerships and new product launches to increase their product offerings. For instance, in January 2020, Illumina and Roche entered into a partnership for improving patient access to oncology genomic testing by assay development. Similarly, in June 2021, the Center for Aquaculture Technologies collaborated with Neogen Corporation to provide high-quality genotyping services tailored to aquaculture producers’ specific demands.

Request a free sample copy or view report summary: Genotyping Market Report

Genotyping Market Report Highlights

The reagents & kit segment accounted for the largest share of 61.6% in the market in 2021. This is attributed to increased demand for genetic testing, increased R&D spending, and increased genotyping testing volumes

PCR segment dominated the market in 2021, whereas sequencing is expected to expand at the highest CAGR during the forecast period. This is due to advantages of the technique, such as low cost per sample, reduced bias as compared to arrays, comparative analysis across samples with no reference genome

Pharmacogenomics is estimated to be the fastest-growing application segment during the forecast period due to increased usage of genotyping in drug development to reduce attrition of products in clinical development

North America accounted for the largest market share in 2021, owing to proactive government measures, high disease prevalence, technological advancements, and advanced healthcare infrastructure

Genotyping Market Segmentation

Grand View Research has segmented the global genotyping market based on product, technology, application, end-use, and region:

Genotyping Product Outlook (Revenue, USD Million, 2018 - 2030)

Instruments

Sequencers & Amplifiers

Analyzers

Reagents and kits

Services

Genotyping Services

Genotyping Technology Outlook (Revenue, USD Million, 2018 - 2030)

PCR

Real-time PCR

Digital PCR

Capillary Electrophoresis

Amplified Fragment Length Polymorphism

Restriction Fragment Length Polymorphism

Single-Strand Conformation Polymorphism

Microarrays

DNA Microarrays

Peptide Microarrays

Others

Sequencing

Next Generation Sequencing

Pyro Sequencing

Sanger Sequencing

Matrix-Assisted Laser Desorption/Ionization-Time of Flight (Maldi-TOF) Mass Spectroscopy

Others

Genotyping Application Outlook (Revenue, USD Million, 2018 – 2030)

Diagnostics

Drug Discovery and Development

Personalized Medicine

Academic Research

Agriculture

Others

Genotyping End-Use Outlook (Revenue, USD Million, 2018 – 2030)

Pharmaceutical And Biopharmaceutical Companies

Diagnostics And Research Laboratories

Academic Institutes

Others

Genotyping Regional Outlook, by Revenue (USD Million, 2018 - 2030)

North America

U.S.

Canada

Europe

Germany

U.K.

France

Italy

Spain

Asia Pacific

China

India

Japan

Australia

South Korea

Latin America

Brazil

Mexico

Argentina

MEA

South Africa

Saudi Arabia

UAE

List of key players in the Genotyping Market

Illumina Inc.

Thermo Fisher Scientific Inc.

Qiagen Inc.

F. Hoffmann-La Roche Ltd.

Fluidigm Corporation

Danaher Corporation

Agilent Technologies

Eurofins Scientific Inc.

GE Healthcare Inc.

Bio-Rad Laboratories Inc.

[industryforecastnews]

Genotyping Market Size Worth $37.1 Billion By 2024 | Global and Regional Forecast | Grand View Research, Inc.

The global genotyping market size is expected to reach USD 37.1 billion by 2024 according to a new report by Grand View Research, Inc. The increasing demand for genotyping tests to evaluate drug efficacy and safety is one of the major drivers for the genotyping market. Genotyping tests are widely used in selecting a highly responsive, patient population subset against a specific drug candidate before initiating clinical trials. The rising need for affordable genotyping services coupled with the high demand for personalized medicines is also expected to propel the market growth. 

Major pharmaceutical companies are collaborating with diagnostic manufacturers for the development of novel biomarker-based therapeutics. Significant opportunities for the growth of this market are anticipated due to the above-mentioned collaborative initiatives. 

The increasing awareness for prenatal genetic testing pertaining to early detection of chromosomal abnormalities in the high-risk population, the introduction of technological advancements, and the increasing R&D funding are the other factors accentuating the market growth over the forecast period. 

The rising prevalence of genetic diseases, such as Parkinson’s, turner syndrome, and Alzheimer’s is the high impact rendering driver for the market growth. Genotyping facilitates rapid sequencing and the early diagnosis of these aforementioned diseases further aid healthcare professionals to decide on probable treatment options.

Companies are undertaking R&D initiatives for the development of advanced products to cater to the increasing demands of the target population. For instance, in 2014, Fluidigm Corporation introduced the Juno 96.96 Genotyping IFC that analyzes a large number of DNA samples for Single Nucleotide Polymorphisms (SNPs) in a short time span.

Browse Full Report (Tables & Figures) @ https://www.grandviewresearch.com/industry-analysis/genotyping-market

Contact Us:

Grand View Research, Inc. 201 Spear Street 1100, San Francisco, CA 94105 United States

Phone: 

1-415-349-0058

Toll Free: 

1-888-202-9519

[starmarketingz]

What You Should Do With Your MLM Software

One absolutely remarkable application that many people overlook is its capacity to improve your SEO elements and divert more relevant visitors to your website. You can start an Ecommerce business by creating your own Ecommerce portal (website). There are numerous open-source eCommerce technologies available. Every niche, including multi-level marketing organisations, has a software product that meets their demands. Different organisations or groups may be working on strikingly similar enterprises and launching them on the same day, even if they are unaware of one another. A total of 52 markers showed significant relationships with at least one of the predicted attributes, suggesting that they could be used for marker-assisted breeding. Because of the discovery of additional marker-trait connections, it is possible that both marker approaches should be used in genome-wide association studies. Furthermore, when the results were compared to those generated utilising the Illumina GoldenGate BeadArray Technology, it was discovered that the amount of connections for corresponding traits observed differed depending on the marker system. The set of winter barley cultivars was re-analyzed using Diversity Arrays Technology (DArT) markers to uncover additional associations and to determine whether the marker type changes the outcome of association genetics investigations.

 A set of about 100 winter barley (Hordeum vulgare L.) cultivars was previously genotypically characterised by single nucleotide polymorphism (SNP) markers using the Illumina GoldenGate BeadArray Technology to detect associations with phenotypic data estimated in three-year field trials. Most other platforms are multi-tenant, which implies that all customers are essentially using the same one-size-fits-all platform, with only data security separations given. Three indices, including the Simple Ratio Index (SRI), the Normalized Difference Spectral Index (NDSI), and the Differential Spectral Index (DSI), were created for correlation analysis and to identify the best wavelength combination for biochemical components. In the aforementioned calculations, the reflectance of two random wavelengths was utilised to compute the value of SRI, NDSI, and DSI, respectively, until all wavelength combinations were used. Pearson correlation analysis was then performed on the resulting SRI, NDSI, and DSI. Finally, the traits with an adequate coefficient covariant and normalised distribution underwent hyperspectral trait extraction and Pearson correlation analysis for GWAS analysis. The biological components that did not match the aforementioned condition will not be employed in subsequent correlation analysis.

Air-dried rice seeds were sent to the China National Rice Research Institute (CNRRI) in Zhejiang province, China, to be measured for four biochemical components important for determining rice quality based on national rice standards NY/T593, including Crude Protein Content (PC), Amylose Content (AC), Gel consistency (GC), and Alkali Spreading Value (ASV) (Table 1). Fig. 1 summarises the complete description of the analytical workflow chart for this study. The following criterion was used to evaluate the dataset's validity during statistical analysis: if the data was not regularly distributed, the dataset was rejected. To acquire hyperspectral data, approximately 3 grammes of rice seeds were employed. To collect hyperspectral data, an ASD FieldSpec4 Hi-Res Spectroradiometer (Serial number 18577, Analytical Spectral Devices, Inc., Boulder, Colorado, USA) with a wavelength range of 350-2500 nm was employed. The spectroradiometer automatically repeated the spectrum acquisition process three times for each sample before averaging them to represent the sample's mean spectral reflectance. Vendors might sometimes include unnecessary mandatory features and charge more for them. The grain of rice

 In a petri dish, grains were placed (diameter: 8 cm). Rice seeds were harvested from five plants of each rice type and tested for nine phenotypic features as planned (Table 1). After harvesting, rice seeds were collected and dried naturally by air-drying before being placed in labelled paper sample bags and delivered to Zhejiang University's Key Laboratory of Spectroscopy Sensing (KLSS). All samples' average spectra were extracted. Before re-sequencing, leaf samples were wrapped in aluminium foil and placed in liquid nitrogen for 2 hours before being stored at 80 °C overnight. We compiled the greatest materials available on the internet to assist you in launching your own software company. The Vienna General Hospital developed and implemented a fuzzy and knowledge-based system to identify and monitor NIs in intensive care units (ICUs) in accordance with the European Surveillance System HELICS (NI definitions drawn from the Centers for Disease Control and Prevention (CDC) guidelines).

Contact Us for MLM Software In India

 Our Network : MLM Software | MLM Software in Jaipur | MLM Software in Bhopal | MLM Software in Lucknow | MLM Software in Kolkata

www dot mlmsoftwarez dot in

Helplines : +91-92140-60999

WhatsApp : +91-92140-60999

This content originally appeared on LinkedIn Pulse - the place to gain and share knowledge, empowering people to learn from others and better understand the world.

[marketreportoutlook]

Single Nucleotide Polymorphism Genotyping Market Size, Share, Growth Opportunity and Trends by Growing CAGR till 2026

The global Single Nucleotide Polymorphism Genotyping Market research report 2021 available on DecisionDatabases covers top company players in various countries along with analyzing the market trends and growth rate. Segment analysis by types and application helps in bifurcating the Single Nucleotide Polymorphism Genotyping Market and understand each product type. This report provides information on various market factors such as market size, share, manufacturer's data, growth, and forecast till 2026

The key market players for the global Single Nucleotide Polymorphism Genotyping market are listed below:

Illumina

Luminex Corporation

Agilent Technologies

Affymetrix

Qiagen

Applied Biosystems

Bio-rad

Roche

Beckman Coulter

Enzo Life Sciences

Douglas Scientific

HuaGene Biotech

Sequenom

Benegene

BGI

GenScript

Ocimum Biosolutions

Generay Biotech

Beijing Sunbiotech

Others

Click here to get a FREE Sample Copy of the Single Nucleotide Polymorphism Genotyping Market Research Report @ https://www.decisiondatabases.com/contact/download-sample-26639

The Global Single Nucleotide Polymorphism (SNP) Genotyping Market Report is equipped with market data from 2016 to 2026. The report gives a market overview covering key drivers and risk factors. The report is bifurcated by top global manufactures mentioning sales, revenue, and prices as applicable. It also evaluates the competitive scenario of the leading players. The report expands to cover regional market data along with type and application. The report forecasts sales and revenue from 2021 to 2026. The detailed sales channel is also covered in the study.

COVID-19 Impact Analysis on Single Nucleotide Polymorphism Genotyping Market

The global pandemic COVID-19 has affected the Single Nucleotide Polymorphism (SNP) Genotyping market directly or indirectly. This study covers a separate section giving an explicitly clear understanding of the aftereffects of this pandemic. The detailed study highlights the probable outcomes of this global crisis on the Single Nucleotide Polymorphism (SNP) Genotyping industry. The impact study on production, supply-demand, and sales provides a holistic approach to the future.

Do You Have Any Query Or Report Customization? Ask Our Market Expert @ https://www.decisiondatabases.com/contact/ask-questions-26639

Why Purchase this Report?

A robust research methodology has been followed to collect data for the report. Data, thus collected passes through multiple quality checks to ensure the best quality is served.

The report gives a holistic view of the competitive scenario of the Single Nucleotide Polymorphism (SNP) Genotyping market

The latest product launches along with technological changes and development are covered in the report.

The data analysis in the report helps in understanding the anticipated Single Nucleotide Polymorphism (SNP) Genotyping market dynamics from 2021 to 2026.

DecisionDatabases has a vast repository of data, therefore, we can accommodate customized requirements also.

The graphs, tables and pie charts, and info-graphics covered in the report will help in a better understanding of the report.

The market drivers, restraints, upcoming opportunities, and anticipated restraints cited in the report will assist in making an informed decision.

To better understand the market scenario, the Single Nucleotide Polymorphism (SNP) Genotyping market is segmented as below:

By Types:

Transversion

Transition

By Applications:

Diagnostics

Animal

Plant

Research

Others

By Regions:

North America (U.S., Canada, Mexico)

Europe (U.K., France, Germany, Spain, Italy, Central & Eastern Europe, CIS)

Asia Pacific (China, Japan, South Korea, ASEAN, India, Rest of Asia Pacific)

Latin America (Brazil, Rest of L.A.)

The Middle East and Africa (Turkey, GCC, Rest of Middle East)

The content of the study subjects includes a total of 14 chapters:

Chapter 1: To describe Single Nucleotide Polymorphism (SNP) Genotyping product scope, market overview, market opportunities, market driving force, and market risks. Chapter 2: To profile the top manufacturers of Single Nucleotide Polymorphism (SNP) Genotyping, with price, sales, revenue, and global market share of Single Nucleotide Polymorphism (SNP) Genotyping in 2018 and 2019. Chapter 3: The Single Nucleotide Polymorphism (SNP) Genotyping competitive situation, sales, revenue, and global market share of top manufacturers are analyzed emphatically by landscape contrast. Chapter 4: The Single Nucleotide Polymorphism (SNP) Genotyping breakdown data are shown at the regional level, to show the sales, revenue, and growth by region, from 2015 to 2020. Chapter 5 and 6: To segment the sales by type and application, with sales market share and growth rate by type, application, from 2015 to 2020. Chapter 7, 8, 9, 10 & 11: To break the sales data at the country level, with sales, revenue, and market share for key countries in the world, from 2016 to 2021 and Single Nucleotide Polymorphism (SNP) Genotyping market forecast, by regions, type, and application, with sales and revenue, from 2021 to 2026. Chapter 12, 13 & 14: To describe Single Nucleotide Polymorphism (SNP) Genotyping sales channel, distributors, customers, research findings and conclusion, appendix, and data source.

Directly Purchase the Complete Global Single Nucleotide Polymorphism Genotyping Market Research Report @ https://www.decisiondatabases.com/contact/buy-now-26639

About Us:

DecisionDatabases.com is a global business research report provider, enriching decision-makers, and strategists with qualitative statistics. DecisionDatabases.com is proficient in providing syndicated research reports, customized research reports, company profiles, and industry databases across multiple domains. Our expert research analysts have been trained to map client’s research requirements to the correct research resource leading to a distinctive edge over its competitors. We provide intellectual, precise, and meaningful data at a lightning speed.

For more details: DecisionDatabases.com E-Mail: sales@decisiondatabases.com Phone: +91 90 28 057900 Web: https://www.decisiondatabases.com/

[soumyafwr]

Single Nucleotide Polymorphism (SNP) Genotyping Market Size, Analysis and Forecast 2031

[biomedgrid]

Biomed Grid | Hybrid Rice Technology: An Overview

Introduction

The prevalence of today’s environmental contaminants is unprecedented. The Toxic Substance Control Act Chemical Substance Inventory lists over 85,000 chemicals in the U.S. market [1]. Adapting to persistent organic pollutants (POPs) exposures is difficult, particularly if adaptive responses require novel genetic variation [2]. An individual’s fitness is influenced by the sum of all stressors, which can be additive, antagonistic, and/or synergistic [3-5]. Devising effective long-term risk-assessment and mitigation strategies is complicated further by human-induced selection pressures on natural populations (climate change, habitat conversion…), jeopardizing organisms’ abilities to survive and adapt to acute and chronic environmental contaminants. Identifying and quantifying such adaptations in individuals and populations in their natural setting is difficult. Yet, technological advances in next generation sequencing (NGS) and transcriptomics provide an opportunity to infer statistically and biologically relevant information within complex but manageable data sets.

POPs are toxic organic compounds resistant to environmental degradation. Most are anthropogenic, lipid-soluble and can cause adverse impacts on the environment and human health. Many POPs are industrial chemicals - solvents, pesticides, insecticides and fungicides, pharmaceuticals, polychlorinated biphenyls (PCBs), dioxins (PCDD), polyfluorinated dibenzofurans (PCDFs), etc. [6,7]. Due to their general use, POPs have high environmental concentrations; many are hydrophobic and bioaccumulate through the food chain due to their slow rate of metabolism [8-10]. Human and animal exposures are mostly through diet (90%), environmental exposures, and during embryo/fetal development via maternal deposition. Chronic POPs exposures can result in acute and chronic toxicity, demonstrated by developmental defects, chronic illnesses, and increased mortality [6]. Some are categorized as carcinogens [11] while many are endocrine disruptors [12-14] and may affect nervous, immune, digestive, urinary and reproductive systems [6]. Low-level exposure to POPs during critical fetal development stages can have a lifetime effect [12-15]. POPs concentrations in human serum increase with age and seem to be higher in females than males [16]. Evolutionary responses and adaptations to POPs have been documented since the mid-20th century; initially as pesticide resistance cases among invertebrates and plants [17,18], then among other natural populations, including vertebrates and mammals [19,20]. Although industrial toxic chemicals were provoking rapid evolutionary response among natural populations, their effects were mostly ignored.

To evaluate temporal and spatial exposure risks, government agencies study the most environmentally prevalent POPs by examining bioavailability and dose-response relationships in the laboratory setting [21]. Such assessments are limited within relatively static laboratory settings. For organisms exposed to a mixture of POPs, the adverse effects are assumed to be additive as mixtures of POPs can result in synergistic effects, enhancing the toxicity of each compound [3-5]. However, responses to POPs are complex and should be carefully considered when quantifying evolution’s role in mechanisms of sensitivity and resistance to complex mixtures of pollutants within and between natural, genetically variable populations [22,23]. Evolutionary changes due to a chronic POP exposure can be quantified in just a few generations [24,25] and include physiological, genetic and epigenetic transgenerational effects influenced by natural selection: studies utilizing natural populations report phenotypic and molecular consequences, including increased mutation rates, receptor desensitization, phenological traits and epigenetic effects [26,27]. While some exposure effects are adaptive, others reduce population size, causing inbreeding depression or genetic drift [28,29] and decreased genetic variation, compromising the ability to adapt to future stressors. Adaptation to POPs can evolve at a cost, such as increased subsequent sensitivity to oxidative stress [30]. Risk assessment of environmental exposures to complex chemical mixtures should not be limited to often oversimplified and outdated controlled laboratory bioassays focused on robust acute and chronic toxicity endpoints such as survival and reproductive viability of model organisms lacking inherent genetic variation.

The post-industrial age of overwhelmingly complex chemical exposures coupled by recent technological advancements in NGS methodology allows for the utility of diverse non-model organisms within an evolutionary context in public health risk assessment. Scientists started using population genomic approaches to study natural populations lacking robust genomic resources a decade ago. Given that genome sequences of non-model organisms are accumulating at an unprecedented pace, with 234 animal and 319 contig genome assemblies currently in development [31], technological advancements in high-throughput sequencing from non-model organisms generate critically important data to infer complex genotype- environment interactions in a natural setting. Population genomic studies target the underlying variation found in the DNA among individuals and populations. They also utilize genome-wide sampling of sequence variation under the premise that demography and the evolutionary history of populations affect neutral loci similarly, whereas loci under selection will be affected differently [32]. Data of multiple, although individually analyzed, loci from natural populations enables studies of the genomic evolution, acclimatization, and adaptation to strong selective pressure such as pollution exposure in natural environment. Such data sets can yield insights about population processes and variance of allelic diversity within and between populations. The advantage is that an a priori choice of biomarkers of an adverse effect is not necessary, which is important when organisms are exposed to complex chemical mixtures in their natural environment and biomarkers of exposure are not well established [33]. Moreover, adaptation-related projects looking for genomic signatures of selection within and between natural populations can take advantage of established adaptative phenotypes to environmental gradients.

A typical population genomic study platform consists of sequencing strategy design, generation of sequence data, mapping of sequence reads to the assembly, genotyping, and population genetic/ molecular evolutionary analyses. A sequencing strategy includes depth of coverage and utility of individuals vs. pooled samples, number of individuals per population and number of populations, gender, and the need for outgroup species. High-throughput genotyping of millions of markers simultaneously is available for model organisms. Whole transcriptome sequencing has advantages but is expensive since multiple individuals need to be sequenced to represent the population adequately. Moreover, the analysis of short sequence reads depends on an incomplete reference genome to which sequence reads are aligned. Such sequencing platforms generate massive data sets, meaning that inferring statistical and biological relevance can be challenging. Although most non-model natural population genomes are not yet sequenced, reasonably robust, lower throughput, custom platforms are available. Expressed sequence tags (ESTs) have been developed and used as genome-wide gene expression data within and among natural fish populations historically exposed to chemical pollution. New sequencing technologies such as Roche (454) FLX, Illumina Genome Analyzer, ABI SOLiD, and HeliScope sequencing [33] can be used to sequence thousands of transcripts quickly and cost-effectively, making transcriptomic studies possible in virtually any species. Transcriptomics and population genomics can influence studies of diverse species and populations that ask important ecological, physiological, and evolutionary questions with respect to pollutant exposure. High-throughput sequencing allows enough sequencing depth to gain an adequate representation of all the expressed transcripts and has been used for whole transcriptome sequencing [34]. The coding sequences of the expressed transcripts can be analyzed for mutations, altered splice sites, and protein polymorphisms.

Whole transcriptome approaches can identify significant changes in gene expression that are biologically important, but the genomic basis underlying altered patterns of gene expression is mostly unknown. Once many genetic markers became available, population geneticists began scanning genomes for reduced nucleotide diversity, extended linkage disequilibrium, or regions of homozygosity as potential selection signatures. This approach requires that large numbers of loci and genetic markers are statistically analyzed for non-random patterns [35]. At loci under selection, local adaptation and directional selection should reduce genetic variability within populations and increase variation among populations. Loci used in population genomics studies include microsatellites, single nucleotide polymorphisms (SNPs), amplified fragment length polymorphisms (AFLPs), randomly amplified polymorphic DNA (RAPDs), and sequences (e.g., whole-genome sequences). Many genetic markers can be generated without a sequenced genome relatively easily and genomes can be mined without measuring phenotypes, allowing for sampling of individuals without knowing their breeding history. For example, SNP analysis can be performed by mining EST data collections for putative SNPs [36]. If the ESTs were derived from multiple individuals (and multiple populations of interest), putative SNPs can be identified in sequence alignments. Conveniently, any SNPs identified as important through population genomic approaches are already associated with a sequenced gene transcript.

Custom SNP genotyping platforms provide efficient genotyping of thousands of individuals, resulting in biologically important sequence variations from multiple populations. The advantage of AFLPs and RAPDs is that, again, no prior sequence information is necessary. The drawback is that AFLP and RAPD analyses depend on high-quality DNA and provide only dominant markers, so heterozygotes cannot be directly measured, and generated markers are often anonymous or in a nonfunctional area of the genome. Genome-wide association studies (GWAS) are challenging with non-model organisms because they lack an abundance of readily available, high quality, sequenced genomes, and genome-wide genotyping data. To improve the use of NGS data obtained from non-model organisms, new imputation methods such as Link Imputer [37] help infer missing genotypes and facilitate the analysis of non-model organisms sequencing data.

Susceptibility to toxic substances depends on the organism’s genotype and interactions with the polluted environment. Natural populations inhabit spatially and temporally uncontrolled environments where pollutants are present as complex mixtures, so the challenges of “omics” technologies with natural populations are the challenges of basic biological research: which data is biologically meaningful? Considering cost, challenging sample material, lack of biological replicates, and complexity of genotype-environment interactions, choosing an optimal method is difficult. Yet, instead of a single gene, protein, or polymorphism, one can analyze thousands of genes, proteins, and polymorphisms utilizing biologically realistic, genetically variable individuals, extrapolating a population response rather than a strain-specific one. Complementary “omics” approaches offer a better understanding of biological effects at multiple levels: model-organisms are used to study many important questions in biology, population genomics provide insights into the sequence variations that govern differences in gene expression and protein polymorphisms, while transcriptomics provides insights into altered protein levels. A focused approach, using known POP inducers and inhibitors present in such mixtures and analyzing responses of cellular and tissue targets, can provide insights into mechanisms of toxicity seen in natural populations and help devise a more comprehensive risk assessment strategy. Thus, just as the integration of laboratory and field studies improves our knowledge of genes and proteins, so is the integration of laboratory and field studies critical for “omic” approaches and public health risk assessment modeling.

Read More About this Article: https://biomedgrid.com/fulltext/volume5/hybrid-rice-technology-an-overview.000865.php

For more about: Journals on Biomedical Science :Biomed Grid | Current Issue

[sachincmi]

SNP Genotyping and Analysis Market to Gain Excellent Traction as Industry Leaders Continue R&D Activities to discover SARS-CoV-2 variants

Single nucleotide polymorphism (SNP) genotyping refers to the measurement of DNA differences between individuals belonging to a particular species. It's a form of genomics, which basically is the analysis of general genetic variation in the human body. SNP genotyping and analysis involves obtaining DNA samples from the blood or tissue samples of various people. The DNA is extracted by using centrifugal pressure and then examined with a DNA sequencing machine. The results are analyzed, then compared with previous samples collected. There are different methods that are employed in measuring genetic differences between people, although there are some that seem to be the most popular.

There are a variety of reasons why the SNP is needed for a DNA test. SNPs can be used to prove the existence of certain diseases, such as breast cancer, diabetes, or asthma. They can also provide insight into the cause of diseases, like Alzheimer's disease, to find out if the disease may have a genetic basis. CSNB stands for the Coding Single Nucleotide Frame Analysis and it is one of the oldest and most effective methods. It was first used by the Swedish government back in 1970, to assess the potential health risks of women using estrogen.

Read more @ https://coherentmarketinsights-cmi.blogspot.com/2020/12/snp-genotyping-and-analysis-market-to.html

[the-madhuri]

Global Biochip Scanner Market-Industry Analysis and Forecast (2019-2027) – By Type, End User, and Region.

Global biochip scanner market size was US$ XX Bn in 2019 and is expected to reach US$ XX Bn by 2027, at a CAGR of ~18% during the forecast period.

Global Biochip Scanner Market

The report study has analyzed the revenue impact of COVID -19 pandemic on the sales revenue of market leaders, market followers, and market disrupters in the report, and the same is reflected in our analysis.

Market Definition

Biochips are miniature version of the laboratories and are the most significant part of molecular biology. Biochips are generally used to perform thousands or hundreds of biochemical reactions at the same time. A biochip scanner is a device that is used to discover and obtain fluorescence signal data from biochips or biological microchips and these devices consist of a laser to emit a laser beam and scan the particular rows of the biochips.

Market Dynamics

A biochip scanner market has witnessed an ample growth from the past few years. The growth of the biochip scanner market is primarily driven by its growing significance in various biomedical applications. An increasing requirement to reduce turnaround time, rising demand of biochip scanners for researches and diagnostics activities to perform clinical tests, growing technological advancements and rising applications of biochips, ongoing research and development activities in large-scale genomic and proteomic field and advances in nanotechnology are expected to improve growth of the market during the forecast period.

However, high cost of biochip scanners, risks of hazardous problems of individual privacy and high complexity of biological systems are major restraining factors that could hamper the growth of the market.

Global Biochip Scanner Market: Segmentation Analysis

By type, the DNA chip segment dominated the market in 2019 and is projected to witness fast growth at a CAGR of XX% during the forecast period. Increasing investments in research activities and rising demand for next-generation and advanced genetic disorder diagnosis and detection tools are attributed to the growth of the market. A rising adoption of DNA chips in applications such as gene expression profiling, to identify novel drugs, to discover the dissimilarities in gene expression levels in cells and to detect the mutations in specific genes is expected to improve growth of the market during the forecast period.

Global Biochip Scanner Market: Regional Analysis

Region-wise, North America held the largest market share in 2019 and is expected to maintain its dominance at a CAGR of XX% during the forecast period. The US and Canada are the major key contributors behind the growth of the market. The growth is attributed to the growing technological advancements in the biomedical field across the region.

Growing adoption of biochip scanners in research laboratories and increasing use of biochip scanning technology in drug development, clinical research, toxicology studies, diagnostics and in various clinical trials is driving the growth of the market in the NA region.

The objective of the report is to present a comprehensive analysis of the Global Biochip Scanner Market including all the stakeholders of the industry. The past and current status of the industry with forecasted market size and trends are presented in the report with the analysis of complicated data in simple language. The report covers all the aspects of the industry with a dedicated study of key players that includes market leaders, followers, and new entrants. PORTER, SVOR, PESTEL analysis with the potential impact of micro-economic factors of the market have been presented in the report. External as well as internal factors that are supposed to affect the business positively or negatively have been analyzed, which will give a clear futuristic view of the industry to the decision-makers. The report also helps in understanding Global Biochip Scanner Market dynamics, structure by analyzing the market segments and projects the Global Biochip Scanner Market. Clear representation of competitive analysis of key players by Application, price, financial position, Product portfolio, growth strategies, and regional presence in the Global Biochip Scanner Market make the report investor’s guide.

For more information visit the link given belowhttps://www.maximizemarketresearch.com/market-report/global-biochip-scanner-market/70484/

The Scope of Global Biochip Scanner Market

Global Biochip Scanner Market, By Type

• DNA Chips • Lab-On-A-Chip • Protein Chips • Cancer Diagnosis and Treatment • Gene Expression • Single Nucleotide Polymorphism (SNP) Genotyping • Genomics • Drug Discovery • Others (Agricultural Biotechnology, Proteomics, Expression Profiling, High Throughput Screening) Global Biochip Scanner Market, By End User

• Biotechnology & Pharmaceutical Companies • Hospitals & Diagnostics Centers • Academic & Research Institutes Global Biochip Scanner Market, By Region

• North America  US  Canada • Europe  UK  France  Germany  Italy  Spain  Norway  Russia • Asia Pacific  China  India  Japan  South Korea  Australia  Malaysia  Indonesia • South America  Brazil  Mexico  Argentina • Middle East and Africa Global Biochip Scanner Market, Key Players

• Agilent Technologies, Inc • Bio-Rad Laboratories, Inc • Cepheid Inc • Fluidigm Corporation • GE Healthcare • Hoffman-La-Roche Ltd • Illumina, Inc • Ocimum Biosolutions Ltd • PerkinElmer, Inc • Takara Bio Inc • Thermo Fisher Scientific Inc • Merck Millipore • Sigma-Aldrich Corporation • Abbott Laboratories • XX • XX

This report is submitted by Maximize market Research Company

Customization of the report:

Maximize Market Research provides free personalized of reports as per your demand. This report can be personalized to meet your requirements. Get in touch with us and our sales team will guarantee provide you to get a report that suits your necessities.

About Maximize Market Research:

Maximize Market Research provides B2B and B2C research on 20,000 high growth emerging opportunities & technologies as well as threats to the companies across the Healthcare, Pharmaceuticals, Electronics & Communications, Internet of Things, Food and Beverages, Aerospace and Defense and other manufacturing sectors.

Contact info:

Name: Lumawant Godage

Organization Address: MAXIMIZE MARKET RESEARCH PVT. LTD.

Email: sales@maximizemarketresearch.com

Address: Omkar Heights, Sinhagad Road, Manik Baug, Vadgaon Bk,Pune, Maharashtra 411051, India.

Contact: +919607195908

[priyacmi]

DNA/Gene Microarray Market, By Type (oDNA, cDNA), By Application (Genomics, Proteomics, Agricultural biology, Environment, Drug R&D, Gene expression and SNP analysis, Cancer/oncology, Others), and By Region (North America, Latin America, Europe, Asia Pacific, Middle East & Africa) - Size, Share, Outlook, and Opportunity Analysis, 2020 - 2027

A DNA microarray or chip is a semiconductor surface on which sequences of many varied genes are bonded to probes. DNA microarrays are used to quantify expression levels of numbers of genes simultaneously or to genotype multiple regions of a genome. The approach finds application in drug R&D, clinical diagnosis, agriculture, environment control, and other sectors.

The global DNA/gene microarray market is estimated to account for US$ 3,018.3 Mn in terms of value in 2020 and is expected to reach US$ 7,693.0 Mn by the end of 2027.

Global DNA/Gene Microarray Market: Drivers

Increasing adoption of genetic testing is expected to propel growth of the global DNA/gene microarray market over the forecast period. For instance, in April 2020, Axovant Gene Therapies collaborated with Invitae Corporation, a provider of advanced medical genetics, to offer free genetic testing in the U.S. and Canada for pediatric lysosomal storage disease.

Moreover, development of novel microarray technology is also expected to fuel growth of the global DNA/gene microarray market over the forecast period. For instance, in December 2019, PathogenDx, Inc. was awarded two US Patents for Tandem PCR + Microarray Hybridisation technology.

North America held dominant position in the global DNA/gene microarray market in 2019, accounting for 34.1% share in terms of value, followed by Europe and Asia Pacific, respectively

Figure 1. Global DNA/Gene Microarray Market Share (%), by Value, by Region, 2019

Global DNA/Gene Microarray Market: Restraints

Lack of technically trained resources, especially in emerging economies, is expected to hinder growth of the global DNA/gene microarray market. Technologically versed and skilled resources are a prerequisite for using DNA/gene microarrays and sequencers. Shortage of such trained personnel is expected to limit market growth.

Moreover, chip compatibility issues are also expected to limit the market growth. A company’s microarray is compatible only with its scanner, fluidics station, autoloader, and operating software alone wherein the manufacturers strive to maintain proprietary rights by following a closed system. Such system specificity principle is believed to create entry barriers for upcoming and new players in the market.

Global DNA/Gene Microarray Market: Opportunities 

R&D in cancer is expected to offer lucrative growth opportunities for players in the market. For instance, in April 2020, researchers from National Defense Medical Center, Taiwan, reported use of DNA microarray gene expression profiles in a research to assess the immunofunctionomes of ovarian clear cell carcinoma in early and advanced stages.

Moreover, increasing prevalence of cancer is also expected to aid in growth of the market. For instance, according to the American Cancer Society, in 2019, there will be an estimated 1,762,450 new cancer cases diagnosed and 606,880 cancer deaths in the U.S.

The global DNA/gene microarray market was valued at US$ 2,640.7 Mn in 2019 and is forecast to reach a value of US$ 7,693.0 Mn by 2027 at a CAGR of 12.4% between 2020 and 2027.

Figure 2. Global DNA/Gene Microarray Market Value (US$ Mn), and Y-o-Y Growth (%), 2019-2027

Market Trends/Key Takeaways

DNA microarray is effective and accurate in determining the presence of pathogens in cannabis. According to a November 2019 study results released by PathogenDx, Inc., end-point PCR technologies such as Sequencing and DNA microarray are more accurate in determining the presence of pathogens in cannabis.

Single Nucleotide Polymorphism (SNP) chips have found to give false positive results. According to a study published in the journal bioRxiv in June 2019, SNP chips used by direct-to-consumer genetic testing companies have a false discovery rate of over 85% when screening for very rare variants.

Global DNA/Gene Microarray Market: Competitive Landscape  

Major players operating in the global DNA/gene microarray market include, Affymetrix, Inc., Illumina, Inc., Agilent Technologies Inc., Roche NimbleGen Inc., Sequenom, Inc., Biometrix Technology Inc., LC Sciences, Life Technologies Corp., Lifegen Technologies LLC, Microarrays Inc.

Global DNA/Gene Microarray Market: Key Developments  

Major players in the market are focused on launching new products to expand their product portfolio. For instance, in March 2020, Agilent Technologies Inc. launched Agilent GenetiSure Cyto microarrays for prenatal and postnatal research.

Major players in the market are also focused on adopting collaboration and partnership strategies to enhance their market share. For instance, in July 2019, PathogenDx, Inc. entered into a strategic sales and service distribution partnership with Zef Scientific in Canada.

About Us:

Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients achieve transformational growth by helping them make critical business decisions.

 What we provide:

·         Customized Market Research Services

·         Industry Analysis Services

·         Business Consulting Services

·         Market Intelligence Services

·         Long term Engagement Model

·         Country Specific Analysis

  Contact Us:

Mr. Shah

Coherent Market Insights Pvt. Ltd.

Address: 1001 4th ave, #3200 Seattle, WA 98154, U.S.

Phone: +1-206-701-6702

Email: sales@coherentmarketinsights.com

  Source

https://www.coherentmarketinsights.com/market-insight/dna-gene-microarray-market-3825

[databridgemarketresarch]

Global Genotyping Market – Industry Trends and Forecast to 2024

Market Definition: Global Genotyping Market

Genotyping is a technique of defining genetic make-up differences of an individual by examining the individual’s DNA sequence by means of the biological assays and for comparing it to other individual’s sequence. Genotyping enables researchers to explore genetic variants such as single nucleotide polymorphisms (SNPs) and large structural changes in DNA.

GET SAMPLE REPORT HERE : https://databridgemarketresearch.com/request-a-sample/?dbmr=global-gene-synthesis-market

Gene Synthesis is a synthetic biology method which is used to create artificial genes in a laboratory. It is also known as DNA printing. They are artificial creation of the deoxyribonucleic acid or DNA. It has a crucial role in synthetic biology and biotechnology and also it is an important tool for various fields like vaccine development, molecular engineering, gene therapy, and heterologous gene expression in recombinant DNA technology. They are recently been used to conduct viral research so that they can produce safer and effective DNA vaccines. With gene synthesis it is possible to build variant genes, libraries and even increase the function of protein. It can also be used in designing cancer enzymes and diagnosis of viral genomes for vaccine development.

According to Data Bridge Market Research new Market report, global gene synthesis market will account to an estimated USD 3,542.49 million in 2018 growing at a CAGR of 23.60% during the forecast period of 2019 to 2026.

Segmentation: Global Gene Synthesis Market

Global gene synthesis market is segmented on the basis of products and services, applications, method, end- user and geography. By Products & Services (Consumables, Software, Services Market), Application (Diagnostics, Therapeutics, Research & Developmental Activities, Other Applications), Method (Solid Phase Synthesis, Chip based DNA synthesis, PCR based enzyme synthesis), End-User (Academic & Research Institutes Market, Diagnostic Laboratories Market, Biotech & Pharmaceutical Companies Market, Other Markets), Geography (North America, South America, Europe, Asia-Pacific, Middle East and Africa)

INQUIRE BEFORE BUYING : https://databridgemarketresearch.com/inquire-before-buying/?dbmr=global-gene-synthesis-market

Key Market Competitors:

Few of the major competitors currently working in the gene synthesis market are Thermo Fisher Scientific, Inc., Genewiz, Eurofins Scientific, ATD Bio Ltd., OriGene Technologies, Inc., Bioneer Corporation, Atum, Integrated DNA Technologies, Inc., GenScript, Eurogentec, Twist Bioscience., BioCat GmbH, LGC Biosearch Technologies, Eton Bioscience, Inc., Quintara Biosciences, Bio Basic Inc., SBS Genetech Co., Ltd., Merck KGaA among others.

READ MORE

CONTACT US:

Customer Support 24*7

USA Number – +1 888 387 2818 (Toll – Free)

Europe Number – +44 208 089 1725

Asia Pacific Number – +81 34 520 8959

Skype.Address: databridgemarketresearch

Website :https://databridgemarketresearch.com